New Insights into Bexicaserin and Its Impact on Seizures
H. Lundbeck A/S has exciting news regarding their investigational treatment, bexicaserin, particularly for those grappling with Developmental and Epileptic Encephalopathies (DEEs). This breakthrough comes as the company prepares to unveil the comprehensive findings from the open-label extension of their Phase 1b/2a PACIFIC clinical trial at the upcoming International Epilepsy Congress. The results will provide vital information on the medication's long-term impact on seizure frequency, a critical issue for many patients dealing with these rare yet debilitating conditions.
Understanding Developmental and Epileptic Encephalopathies
DEEs represent a challenging category of rare epilepsy, often marked by drug-resistant seizures and frequent problematic activities visible in EEG tests. These conditions are characterized not only by the occurrence of seizures but also by developmental issues, making treatment particularly complex. Despite these challenges, bexicaserin has emerged as a hopeful candidate, showing promise in reducing the frequency of seizures significantly during clinical investigations.
Clinical Trial Findings and Future Aspirations
In the trial's open-label extension, participants observed a substantial median reduction of 59.3% in countable motor seizure frequency. Impressively, over half of the individuals involved experienced sustained seizure reductions exceeding 50% compared to their baseline counts before starting the PACIFIC trial. These results not only highlight the drug's effectiveness but also affirm its tolerability, with no new safety concerns being reported.
During these trials, Dr. Johan Luthman, EVP at Lundbeck, expressed his optimism regarding bexicaserin's potential. He highlighted the significant step forward this could mean for patients with DEEs, who currently have limited treatment options. Additionally, emerging data from preclinical studies hints at bexicaserin's ability to address the risk of sudden unexpected death in epilepsy (SUDEP), potentially transforming the care landscape for these patients.
Preclinical Data and Future Trials
Lundbeck is not just stopping at clinical trials; preclinical data on bexicaserin includes investigations into its effectiveness across different seizure models, including those related to SUDEP. The drug has demonstrated a notable reduction in seizures and respiratory arrest in preclinical studies, prompting researchers to further explore its potential in treating other hard-to-manage seizure types, such as absence seizures.
As part of their commitment to treating DEEs effectively, Lundbeck is advancing bexicaserin into late-stage clinical trials globally through the DEEp Program. This initiative aims to understand the drug's safety and efficacy better in various patient demographics, including children and adults suffering from these rare conditions. The DEEp trial comprises two arms: the DEEpSEA trial, which focuses on Dravet syndrome, and the DEEpOCEAN trial, which encompasses other forms of DEEs, including Lennox-Gastaut syndrome.
Presentations at the International Epilepsy Congress
Lundbeck's presence at the International Epilepsy Congress will showcase crucial findings related to bexicaserin. The primary results from the open-label extension study will be shared, along with exciting presentations addressing the modulation of seizures and the overall safety profile of the drug in various models. This level of engagement underscores Lundbeck’s commitment to advancing understanding and treatment of DEEs.
About Bexicaserin
Bexicaserin (LP352), notable for acting as a highly selective 5-HT2C receptor superagonist, is being investigated for its potential to mitigate seizures without the cardiovascular risks linked with other treatments. Currently unapproved for marketing, bexicaserin holds the FDA's Breakthrough Therapy designation, solidifying its role as a promising option for patients aged two years and older.
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company dedicated to improving brain health with over 70 years of experience in the neurosciences. Focused on addressing the complex challenges posed by neurological and psychiatric disorders, Lundbeck is committed to developing innovative medications that leverage deep scientific knowledge and advance patient care around the globe.
Frequently Asked Questions
What is Bexicaserin?
Bexicaserin is an investigational oral treatment being studied for its efficacy in reducing seizures associated with Developmental and Epileptic Encephalopathies.
What was the outcome of the PACIFIC trial?
The PACIFIC trial showed that bexicaserin resulted in a median seizure frequency reduction of 59.3% in participants during the open-label extension.
What are Developmental and Epileptic Encephalopathies?
DEEs are severe forms of epilepsy characterized by drug-resistant seizures and developmental complications, making treatment particularly complex.
How does Bexicaserin work?
Bexicaserin acts as a 5-HT2C receptor superagonist, potentially offering seizure reduction while minimizing cardiovascular risks associated with other treatments.
What future trials are occurring for Bexicaserin?
The DEEp Program includes the DEEpSEA and DEEpOCEAN trials, which are designed to evaluate bexicaserin's safety and efficacy in a broader patient population.
